Venture Investors and the State of Wisconsin Investment Board participated in a $100 million financing round for HistoSonics, which made the announcement today.

The Minneapolis-based HistoSonics is a developer of a non-invasive, novel sonic beam therapy.

According to a release, the funds will be used to support the company’s anticipated commercial launch, support additional clinical trials and expand application development of Edison, the company’s novel histotripsy therapy platform.

Other participants in the funding round included Johnson & Johnson Innovation, Lumira Ventures and Yonjin Venture.